81840-15-5
81840-15-5
Chemical Structure
Vesnarinone
Synonym(s): OPC-8212
- CAS No.: 81840-15-5
- Formula:C22H25N3O4
- Molecular Weight:395.45
IUPAC Name: 6-(4-(3,4-dimethoxybenzoyl)piperazin-1-yl)-3,4-dihydroquinolin-2(1H)-one
InChIKey: ZVNYJIZDIRKMBF-UHFFFAOYSA-N
SMILES: O=C1NC2=C(C=C(N3CCN(C(C4=CC=C(OC)C(OC)=C4)=O)CC3)C=C2)CC1
Biological Activity: Vesnarinone (OPC-8212) is an orally active phosphodiesterase 3 (PDE3) inhibitor. Vesnarinone can increase in calcium flux and decrease in potassium flux. Vesnarinone shows dose-dependent positive inotropic activity. Vesnarinone can be used in heart failure research[1][2][3][4].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
Vesnarinone | 98.52% | Vesnarinone (OPC-8212) is an orally active phosphodiesterase 3 (PDE3) inhibitor. Vesnarinone can increase in calcium flux and decrease in potassium flux. Vesnarinone shows dose-dependent positive inotropic activity. Vesnarinone can be used in heart failure research. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Vesnarinone (Standard) | ≥98% | Vesnarinone (Standard) is the analytical standard of Vesnarinone. This product is intended for research and analytical applications. Vesnarinone (OPC-8212) is an orally active phosphodiesterase 3 (PDE3) inhibitor. Vesnarinone can increase in calcium flux and decrease in potassium flux. Vesnarinone shows dose-dependent positive inotropic activity. Vesnarinone can be used in heart failure research. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
References
- [1]. A Matsumori, et al. Vesnarinone, a new inotropic agent, inhibits cytokine production by stimulated human blood from patients with heart failure. Circulation. 1994 Mar;89(3):955-8. [Content Brief]
- [2]. E Cavusoglu, et al. Vesnarinone: a new inotropic agent for treating congestive heart failure. J Card Fail. 1995 Jun;1(3):249-57. [Content Brief]
- [3]. K Yoneda, et al. Induction of cyclin-dependent kinase inhibitor p21 in vesnarinone-induced differentiation of squamous cell carcinoma cells. Cancer Lett. 1998 Nov 13;133(1):35-45. [Content Brief]
- [4]. Iain Gardner, et al. A comparison of the covalent binding of clozapine, procainamide, and vesnarinone to human neutrophils in vitro and rat tissues in vitro and in vivo. Chem Res Toxicol. 2005 Sep;18(9):1384-94. [Content Brief]
